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Abstract
Gestational diabetes mellitus (GDM) is defined as a glucose intolerance of varying severity with onset or first recognition during pregnancy. 
The prevalence of GDM is growing rapidly worldwide, resulting in numerous and serious complications for both mother and foetus. 
Two major metabolic disorders, insulin resistance and β cells dysfunction, are currently linked to the pathogenesis of GDM, although 
the cellular mechanisms involved in the development of GDM are not yet completely understood. Increasing evidence from clinical and 
experimental studies indicates that adipose tissue dysfunction, characterised by abnormal production of adipokines, is an essential factor 
linked to insulin resistance and GDM. To date, several adipose tissue-derived hormones have been identified, including leptin, adiponec-
tin, resistin, visfatin, apelin, retinol-binding protein 4 (RBP-4), vaspin, and omentin. The relationship of leptin and adiponectin to insulin 
resistance in GDM is relatively well documented, but the molecular mechanisms by which these hormones affect insulin resistance are 
not yet fully known. The other aforementioned adipokines appear to be also important players in the pathophysiology of GDM, although 
their precise function in this complex process remains to be established. 
The aim of this article is to review the literature concerning the relationship between the above-mentioned adipokines and GDM, and to 
clarify their role in the pathophysiology of GDM. (Endokrynol Pol 2014; 65 (2): 134–142)
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Streszczenie
Cukrzyca ciążowa (GDM) jest definiowana jako nietolerancja glukozy, która po raz pierwszy wystąpiła lub została wykryta w czasie ciąży. Za-
chorowalność na GDM szybko wzrasta na świecie, prowadząc do licznych i poważnych powikłań zarówno u matki, jak i płodu. Dwa główne 
zaburzenia metaboliczne, czyli oporność na insulinę i dysfunkcja komórek b, biorą udział w patogenezie GDM, jednak komórkowe mechanizmy 
prowadzące do jej rozwoju nie są jeszcze do końca poznane. Wyniki badań klinicznych i eksperymentalnych wskazują, że dysfunkcja tkanki 
tłuszczowej, charakteryzująca się nieprawidłową produkcją adipokin, jest istotnym czynnikiem związanym z GDM. Do tej pory zidentyfikowano 
kilka hormonów wytwarzanych przez tkankę tłuszczową, w tym leptynę, adiponektynę, rezystynę, wisfatynę, apelinę, białko wiążące retinol 4 
(RBP-4), waspinę i omentynę. Spośród nich stosunkowo dobrze udokumentowany jest związek leptyny i adiponektyny z insulinoopornością w 
GDM, ale molekularne mechanizmy działania obydwu hormonów w tym procesie nie są jeszcze całkowicie wyjaśnione. Pozostałe wyżej wy-
mienione adipokiny wydają się być również istotnymi czynnikami w patofizjologii GDM, chociaż ich dokładna funkcja w tym kompleksowym 
procesie pozostaje niejasna. Celem niniejszego artykułu był przegląd istniejącej literatury dotyczącej związku między wyżej wymienionymi 
adipokinami i GDM oraz wyjaśnienie ich roli w patofizjologii GDM. (Endokrynol Pol 2014; 65 (2): 134–142)
Słowa kluczowe: adipokiny; adiponektyna; cukrzyca ciążowa (GDM); leptyna; omentyna; RBP-4; rezystyna; waspina; wisfatyna
This study was supported financially by funds from the Medical University of Lodz (project no. 502-03/0-160-01/502-04-014).
Introduction
Gestational diabetes mellitus (GDM) is a carbohydrate 
intolerance of varying severity with onset or first 
recognition during pregnancy. It affects 1–14% of all 
pregnancies, depending on racial/ethnic group and 
the diagnostic test employed [1]. However, the recently 
published report by the International Association of 
Diabetes in Pregnancy Study Groups (IADPSG), which 
used new recommendations for the diagnosis of GDM, 
has revealed GDM prevalence to be as high as 17.8% [2]. 
In Poland, 3.4% of pregnant women develop GDM [3]. 
Gestational diabetes mellitus causes numerous and 
serious short- and long-term complications for both 
mother and foetus. In the short term, mothers with GDM 
are at increased risk of delivering a macrosomic infant or 
developing preeclampsia [4], whereas their offspring are 
prone to neonatal hypoglycaemia, hyperbilirubinemia, 
hypocalcaemia, respiratory distress syndrome, and poly-
cythemia [5]. In the long term, GDM women are at mark-
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edly increased risk of developing type 2 diabetes mellitus 
(T2DM) and cardiovascular disease after pregnancy, and 
their offspring are at risk for the development of obesity 
and abnormal glucose metabolism during childhood, 
adolescence, and adulthood [6].
To date, a large number of risk factors associated 
with GDM development have been identified, includ-
ing previous history of GDM or impaired glucose toler-
ance, ethnicity, family history of GDM or T2DM (espe-
cially in first-degree relatives), advanced maternal age, 
previous history of macrosomic baby or of stillbirth or of 
baby with congenital abnormality, pregnancy-induced 
or pre-existing hypertension, other insulin-resistant 
conditions (for example, metabolic syndrome or poly-
cystic ovary syndrome), smoking during pregnancy, 
high parity, and obesity [6]. In respect of obesity, clinical 
and epidemiological studies indicate that this metabolic 
disorder is a major modifiable risk factor for GDM de-
velopment. As estimated, the risk of developing GDM 
is 3.56-fold and 8.56-fold higher in obese and severely 
obese pregnant women, respectively, compared to 
normal-weight pregnant women [7]. In the context of 
the global epidemic of obesity, it should be emphasised 
that there is also a rapidly growing number of obese 
patients among pregnant women, who are at increased 
risk of developing GDM. 
Two major metabolic disorders, insulin resistance 
and b-cells dysfunction, are involved in the pathogene-
sis of GDM, although the cellular mechanisms involved 
in its development are not yet completely understood. 
Accumulating evidence indicates that adipose tissue 
plays a key role in the pathophysiology of GDM since 
it is not only the main site of lipid storage but also an 
endocrine organ responsible for synthesis and secre-
tion of various bioactive molecules, collectively called 
adipokines or adipocytokines. It is now accepted that 
adipose tissue dysfunction, characterised by abnormal 
production of adipokines, represents a pathophysi-
ological link between obesity and diabetes [8]. In this 
context, changes in the expression and secretion of 
several adipose tissue-derived hormones have been 
observed in GDM patients, including leptin, adiponec-
tin, resistin, visfatin, apelin, retinol-binding protein 4 
(RBP-4), vaspin, and omentin. In this review, we discuss 
the roles of these adipokines in GDM, based on recent 
findings in this area. 
Leptin
Leptin, encoded by the ob gene, is a 16-kDa-peptide 
hormone comprising 167 amino acids. It is produced 
predominantly in adipocytes, although its presence has 
also been detected in other tissues, including placenta, 
ovaries, mammary epithelium, bone marrow, and lym-
phoid tissues [9]. Leptin is considered as an essential 
factor in energy homeostasis since it regulates food intake 
and energy expenditure via leptin receptors (ObRs) in 
the central nervous system (CNS), mainly localised in 
the hypothalamus. To date, at least six ObR isoforms (i.e. 
ObRa, ObRb, ObRc, ObRd, ObRe, and ObRf) produced 
by alternative RNA splicing of the db gene have been 
identified, but only four of them are present in humans: 
the long (ObRb), short (ObRa and ObRc), and secretory 
(ObRe) splice variants [10]. Of these, the ObRb receptor 
is believed to be the most important isoform participat-
ing in the transduction of intracellular signals [11]. The 
primary signal transduction pathway of leptin is the 
Janus kinase (JAK)–signal transducer and activator of 
transcription (STAT) signalling (JAK/STAT signalling), 
although other important intracellular signalling routes 
mediating leptin effects have also been found, including 
phosphatidylinositol-3-kinase (PI3K), AMP-activated 
protein kinase (AMPK), and mitogen-activated protein 
kinase (MAPK) [11].
Leptin level is low in lipodystrophic mice with 
severe insulin resistance and its administration into 
these animals restores insulin sensitivity [12]. However, 
adipocyte leptin expression and its plasma circulating 
level are raised in both obese patients [13, 14] and obese 
animal models (except the leptin-deficient ob/ob mouse), 
regardless of whether the obesity is caused by genetic 
defects, hypothalamic lesions, or brown adipose tissue 
deficiency [15–17]. Additionally, exogenous leptin ad-
ministration into obese patients does not cause weight 
loss, suggesting that obese humans are resistant to the 
effects of leptin [18]. The limited leptin transport across 
the blood-brain barrier and/or suppression of the leptin 
signalling pathways in leptin-responsive hypothalamic 
neurons have been proposed to be attributal to the 
leptin resistant state in human obesity [19].
Interestingly, leptin mRNA expression is higher 
in subcutaneous than omental adipocytes and the 
subcutaneous-to-omental ratio of leptin mRNA ex-
pression is markedly higher in women than men [20]. 
Thus, adipose tissue distribution and mass, as well as 
gender, appear to be important factors determining 
plasma leptin concentration, although other factors 
influencing leptin secretion have also been identified, 
including fasting or energy restriction, tumour necrosis 
factor a (TNF-a), glucose, fatty acids, insulin, cortisol, 
and catecholamines [21]. 
Since leptin receptor isoforms are present in muscle, 
liver, adipose tissue, and pancreas, numerous studies 
have revealed direct effects of leptin on glucose and 
lipid metabolism as well as insulin secretion in these pe-
ripheral tissues, independently of CNS. In skeletal mus-
cle, leptin stimulates basal, but not insulin-stimulated, 
glucose uptake through the PI3K-dependent pathway 
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[22]. Additionally, leptin prevents the accumulation of 
lipids in muscle tissue by stimulating fatty acid oxida-
tion through activating AMPK and, in turn, suppression 
of the activity of acetyl coenzyme A carboxylase (ACC). 
Thus, AMPK is considered to be a main mediator of 
leptin action on fatty-acid metabolism in muscle [23].
In isolated hepatocytes, leptin affects glucose me-
tabolism by significant reduction of glucose production 
from different gluconeogenic precursors (i.e. glycerol, 
L-lactate, L-alanine, and L-glutamine) [24] and this 
effect appears to be mediated by PI3K-dependent acti-
vation of phosphodiesterase 3B (PDE3B) [25]. Leptin, 
at physiological concentrations, acts through an intra-
cellular signalling pathway similar to that activated by 
insulin in isolated hepatocytes [25]. Leptin activation 
of PI3K rather than AMPK is required for the lipid-
lowering effect of leptin in liver [26].
The relation between leptin and insulin sensitivity 
in adipocytes is inconclusive so far. There have been 
studies showing no effect of leptin on glucose transport, 
lipoprotein lipase activity, and insulin action in cultured 
rat adipocytes and 3T3-L1 adipocytes [27], whereas 
some others have demonstrated that leptin, at an elevated 
concentration, is able to down-regulate insulin signal-
ling in adipose cells, leading to the inhibition of insulin-
stimulated glucose transport in adipocytes [28]. Therefore, 
further studies are needed to clarify these findings. 
Leptin can also directly affect pancreas function 
through inhibiting b-cell insulin secretion and several 
mechanisms engaged in this process have been proposed, 
including (i) reduction of proinsulin mRNA level in 
pancreatic b-cells under high glucose concentrations, (ii) 
suppression of glucose transport into b-cells, (iii) PI3K-
dependent activation of PDE3B that leads to a reduction 
of cAMP level and, in turn, inhibition of protein kinase 
A (PKA) involved in the regulation of Ca2+ channels and 
exocytosis, and (iv) inhibition of the phospholipase C 
(PLC)/protein kinase C (PKC) pathway [29].
A growing number of studies in pregnancies com-
plicated by GDM have strongly supported the relation-
ship of hyperleptinaemia with GDM [30–33]. Although 
the reasons behind this are not yet known, leptin 
secretion by adipocyte in the presence of increased 
estrogen [34] or/and by placenta [35] is possible. The 
role of leptin in the pathophysiology of GDM has been 
proposed by Chen et al. [31] who revealed significantly 
higher plasma leptin concentration in GDM women 
compared to normal glucose tolerant (NGT) subjects, 
which subsequently significantly decreased after de-
livery reaching a level comparable to the NGT group. 
It should be noted that besides elevated plasma leptin 
concentration in diabetic pregnancy, there is also data 
showing either decreased or unchanged plasma level 
of this adipokine [36, 37].
The relevance of leptin as a predictor of GDM risk 
has been implied by Qiu et al. [38] who demonstrated 
that hyperleptinaemia, independent of maternal 
adiposity, in early pregnancy is associated with an in-
creased risk of GDM later in pregnancy and that each 
10 ng/mL increase in leptin concentration is associated 
with a 20% increase in GDM risk.
Particular attention has focused on placenta, where 
leptin is also synthesised and secreted into both the 
maternal and foetal circulation [35]. Placental leptin 
is identical to that from adipose tissue regarding size, 
charge, and immunoreactivity. However, its gene has 
an upstream enhancer and therefore leptin expression 
can be regulated differently in both tissues [39]. Placenta 
contains long and short leptin receptor isoforms that are 
co-localised with leptin to the syncytiotrophoblast at the 
maternal interface [39], suggesting a potential autocrine 
or paracrine effect of leptin on placental function.
There are conflicting reports in respect of placental 
leptin expression during GDM with its either up-regu-
lation [40–42] or down-regulation [36, 43]. The reasons 
for these discrepancies are currently unclear, although 
differences in the material used for testing, i.e. placenta 
versus tissue explants containing non-trophoblast cells 
producing paracrine mediators that may affect leptin 
release, are taken into account [43]. On the other hand, 
it cannot be excluded that increased expression of the 
soluble leptin receptor in placentas of GDM women 
that is capable of binding leptin with a high affinity 
may limit its accessibility to the transmembrane recep-
tor, leading to a reduction of the release of leptin from 
GDM placentas [43].
Adiponectin
Adiponektin (AdipoQ), also known as adipocyte com-
plement-related protein of 30 kDa (Acrp30) and gelatin 
binding protein of 28 kDa (GBP28), is a 244-amino acid 
protein with high structural homology to complement 
C1q [44] as well as TNF-a [45]. AdipoQ is produced 
almost exclusively by white adipose tissue and it oc-
curs in three oligomeric forms: a low-molecular-weight 
trimer, a middle-molecular-weight hexamer, and 
a high-molecular weight (HMW) 12- to 18-mer [46]. Two 
receptors for Adipo Q, namely AdipoR1 and Adipo2, 
with different tissue distributions have been identified 
so far. AdipoR1 is abundantly expressed in skeletal 
muscle, whereas AdipoR2 expression predominates 
in liver [46].
AdipoQ is believed to be an insulin-sensitising 
factor involved in the regulation of glucose and lipid 
metabolism in insulin-sensitive tissues, mainly in liver 
and muscle, in both humans and animals. A connection 
of low AdipoQ level with the development of insulin 
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resistance has been found in mouse models of both 
obesity and, paradoxically, lipoatrophy. In humans, 
plasma AdipoQ level is reduced in T2DM [47] and it is 
more closely related to whole body insulin sensitivity 
than to adiposity [48]. With regard to the involvement 
of AdipoQ in lipid metabolism, it has been observed that 
this adipokine inversely correlates with triacylglycerol 
(TG) level and positively correlates with plasma HDL-
cholesterol concentration [49–51].
Although the insulin-sensitive action of AdipoQ is 
complex and incompletely defined so far, the existing 
evidence suggests that it works by AdipoR1 and AdipoR2 
receptors stimulating fatty acid oxidation in both muscle 
and liver as well as activating glucose uptake in muscle 
and reducing gluconeogenesis in liver through AMPK 
[52]. Additionally, AdipoQ may activate peroxisome 
proliferator-activated receptor a (PPARa), leading to 
an increased fatty-acid oxidation and subsequently de-
creased TG content in liver and skeletal muscle, thereby 
increasing insulin sensitivity (Fig. 1) [46]. 
AdipoQ may also improve insulin signal transduc-
tion via an increase of tyrosine phosphorylation of 
insulin receptor in skeletal muscle [53].
A number of factors regulating AdipoQ expression 
or secretion have been identified both in vitro and in 
vivo. Among them, the insulin-sensitising thiazolidin-
ediones (TZDs), i.e. agonists of peroxisome proliferator-
activated receptor g (PPARg) that as transcriptional 
factor modulates insulin resistance as well as fat cell 
differentiation, and adipogenesis, have been shown 
to enhance the expression and secretion of AdipoQ in 
diabetic patients [54, 55]. Thus, PPARg activity seems to 
be closely related to AdipoQ production. According to 
this, carriers of the rare dominant negative mutations in 
the PPARg gene have very low or undetectable plasma 
AdipoQ concentration [55]. Moreover, both TNF-a and 
IL-6 may reduce human adipocyte AdipoQ mRNA 
expression resulting in insulin resistance [56].
Numerous independent studies have associated 
hypoadiponectinaemia with GDM. Cseh et al. [57] 
demonstrated a significant inverse correlation be-
tween maternal AdipoQ level and increased BMI, 
fasting C-peptide concentration, and C-peptide/ 
/glucose ratio in pregnant women with GDM, while 
others found reduced adipocyte AdipoQ expression 
as well as its decreased plasma concentration in 
GDM women, independently of obesity [58, 59]. Low 
AdipoQ level in normal weight GDM women may 
result from its down-regulation in placenta, which is 
considered as another source of this adipokine [60]. 
It has been demonstrated that AdipoQ is expressed 
in human term placenta, primarily in the syncytio-
trophoblast, and its expression, along with AdipoR1 
and AdipoR2 receptors, is differently regulated by 
TNF-a, IFN-g, IL-6, and leptin, suggesting the signifi-
cance of AdipoQ in adapting energy metabolism at 
the materno-foetal interface [60]. Surprisingly, Lap-
pas et al. [43] did not detect differences in the release 
of AdipoQ from placenta obtained from normal and 
GDM complicated pregnancies. These results are 
currently difficult to explain, and therefore further 
studies are needed in this field.
Besides the association of hypoadiponectinaemia 
with insulin resistance during GDM, a relationship 
between its reduced concentration and β-cell dysfunc-
tion in GDM women has also been reported [61]. Thus, 
AdipoQ appears to be a factor linking insulin resistance 
to β-cell dysfunction in the pathogenesis of diabetes.
Interestingly, plasma AdipoQ level negatively cor-
relates with GDM development among women in 
the first trimester of pregnancy [62], implying that its 
concentration in the bloodstream in early pregnancy 
could be a predictor of GDM development. Addition-
ally, plasma AdipoQ level is reduced in women with 
previous GDM, independently of the prevailing insulin 
sensitivity or the degree of obesity [63]. 
Resistin
Human resistin is a 12.5 kDa cysteine rich peptide 
that is predominantly expressed in peripheral blood 
mononuclear cells (PBMCs), macrophages and bone 
marrow cells, whereas its expression is low in mature 
adipocytes [64]. 
Figure 1. AdipoQ-mediated regulation of glucose and lipid 
metabolism in liver and skeletal muscle. AMPK — AMP-
activated protein kinase; GLUT4 — glucose transporter type 4; 
PPARa — peroxisome proliferator-activated receptor a; TGs — 
triacylglycerols; ↑ increase; ↓ decrease
Rycina 1. Udział AdipoQ w regulacji metabolizmu glukozy i 
lipidów w wątrobie i mięśniach szkieletowych. AMPK — kinaza 
białkowa aktywowana przez AMP; GLUT4 — transporter 
glukozy typu 4; PPARa — receptory aktywowane proliferatorami 
peroksysomów a; TGs — triacyloglicerole; ↑ wzrost; ↓ obniżenie
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In mice, resistin is up-regulated in both genetic 
and diet-induced obesity and its circulating level is 
decreased by TZDs [65]. Additionally, administration 
of anti-resistin antibody into the diet-induced obese 
mice decreases blood glucose level and improves insulin 
sensitivity in these animals [65]. From these findings, 
it has been concluded that this hormone links obesity 
to insulin resistance and diabetes. According to this 
hypothesis, resistin is involved in glucose metabolism, 
thereby it could contribute to hepatic insulin resistance. 
It has been observed that resistin decreases insulin 
receptor and glycogen synthase activity and increases 
the activity of glycogen phosphorylase, leading to an at-
tenuated glycogenesis and an enhanced glycogenolysis 
in liver [66]. However, subsequent studies have failed 
to confirm the association of high resistin expression 
with obesity and increased insulin resistance in various 
rodent models of obesity and diabetes, implying that 
the expression of resistin may be differentially regulated 
among these animal models [64].
In humans, there is disagreement in respect of 
the pathogenic role of resistin in the development 
of insulin resistance and obesity. Several studies 
have supported a positive correlation between obe-
sity, insulin resistance and elevated plasma resistin 
concentration [67, 68], whereas others did not find 
such an association [69, 70]. Therefore, further well-
designed human studies are needed to precisely 
determine the potential involvement of resistin in the 
pathophysiology of obesity and diabetes. Since resis-
tin expression is high in immune cells, it is possible 
that it may play a role in insulin resistance through 
effects on inflammation.
Human resistin is also present in placental tissue, 
mainly in trophoblastic cells [64], but its physiological and 
pathophysiological roles in human normal and complicat-
ed pregnancies are unclear. It has been demonstrated that 
plasma resistin concentration is higher in GDM women 
than NGT pregnant women and non-pregnant women 
[71], and that it correlates with plasma IL-6 concentration, 
but not insulin level, in diabetic subjects. These results sug-
gest that alterations in insulin sensitivity in GDM patients 
could be mediated by inflammatory pathways, in which 
resistin appears to be involved. In another study, plasma 
resistin concentration was also significantly elevated in 
GDM subjects compared to NGT controls and it was in-
dependently associated with markers of adiposity (BMI, 
plasma leptin), TGs, and creatinine [72]. Besides the posi-
tive correlation between plasma resistin level and GDM 
[71], there are studies demonstrating its either decreased 
[73] or unchanged [74] concentration in diabetic pregnant 
women. A recent meta-analysis concerning the relation-
ship of resistin with GDM revealed no difference in plasma 
resistin level between GDM subjects and control pregnant 
women [75]. However, these findings should be treated 
with caution due to considerable heterogeneity among 
analysed studies [75]. Thus, it is clear that further studies 
are required to understand the accurate pathophysiologic 
role of resistin in human diabetic pregnancy.
Visfatin
Visfatin, also known as pre-B cell colony-enhancing fac-
tor (PBEF) or nicotinamide phosphoribosyltransferase 
(NAMPT), is a 52 kDa protein produced mainly by the 
visceral adipose tissue in both humans and mice [76]. Vis-
fatin has been shown to mimic insulin effects by binding 
to the insulin receptor, but in another site than insulin, 
and to reduce plasma glucose level in mice [76]. These 
findings suggest that visfatin could play a regulatory role 
in glucose homeostasis [76]. Indeed, secretion of visfatin 
by adipocytes in vitro in response to glucose exposure 
as well as its increase in plasma of human subjects after 
glucose administration has been reported [77].
Although the exact pathophysiologic role of visfatin 
is not fully elucidated, there are studies showing the as-
sociation of elevated visfatin concentration with T2DM. 
Chen et al. [78] demonstrated higher circulating visfatin 
level in T2DM patients compared to normal subjects. 
Furthermore, some polymorphisms in the visfatin gene 
may play a role in determining T2DM susceptibility, 
possibly by modulating chronic, low-grade inflamma-
tory responses that significantly affect insulin resistance 
[79]. There is evidence supporting the immunoregula-
tory effects of visfatin. Moschen et al. [80] reported that 
in human monocytes, visfatin up-regulates the produc-
tion of several proinflammatory cytokines such as IL-6, 
TNF-a, and IL-1β. Moreover, treatment of human foetal 
membranes with recombinant human visfatin markedly 
increases levels of the aforementioned cytokines [81].
There are no consistent results regarding plasma vis-
fatin level in diabetic pregnant women and its associa-
tion with GDM. For example, Krzyzanowska et al. [82] 
reported markedly higher plasma visfatin concentration 
in GDM women compared to NGT pregnant controls; 
however, there was no relationship between visfatin 
and fasting plasma glucose, plasma insulin, insulin 
resistance, and BMI. Elevated plasma visfatin concen-
tration in GDM women has also been demonstrated by 
others [83, 84]. Lewandowski et al. [83] revealed positive 
correlations of plasma visfatin levels with concentra-
tions of both fasting and post-glucose-load insulin in 
GDM women in the third trimester of pregnancy. Fer-
reira et al. [84] reported an increased plasma visfatin 
level in the first trimester of pregnancy in women who 
developed GDM, suggesting that visfatin could be 
a potential biomarker for predicting GDM. In contrast, 
a reduced plasma visfatin level, by approx. 25%, was 
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detected in women of Chinese origin with GDM com-
pared to healthy pregnant controls [85]. Moreover, there 
was a significant negative correlation between plasma 
visfatin concentration and first trimester BMI as well as 
maternal age [85]. The reasons for these discrepancies 
are currently unknown, although differences in study 
design, including the number of subjects, gestational 
age, and differences in BMI might explain, at least 
partially, the differences among the aforementioned 
studies. Therefore, more restrictive controlled human 
studies are needed to define the significance of visfatin 
in diabetic pregnancy.
Apelin
Apelin is expressed and secreted by both human and 
mouse adipocytes and its production is increased four-
fold upon differentiation of fat cells [86]. To date, several 
active apelin forms have identified, including apelin-36, 
-17, and -13 as well as the pyroglutamated isoform of 
apelin-13, which is produced by a post-translational 
modification of glutamine to pyroglutamine at the N-
terminus [87]. Apelin acts through a specific G protein 
coupled receptor named APJ, which is expressed in 
both peripheral tissues and CNS [87]. 
It has been shown that insulin regulates the expres-
sion and secretion of apelin through the PI3K and PKC 
pathways in mice as well as in murine and human 
adipocytes [86]. Moreover, an increased plasma apelin 
level has been observed in obese and hyperinsulinaemic 
humans, implying that the rise in plasma insulin could 
promote higher plasma apelin concentration in these 
subjects [86]. 
The connection between apelin and T2DM has been 
postulated. A raised apelin level has been found in both 
non-obese patients with impaired glucose tolerance or 
T2DM and morbidly obese patients with T2DM [88, 89]. 
Recently, Dray et al. [90] disclosed a markedly increased 
plasma apelin level in T2DM subjects that positively 
correlated with insulin concentration, glycaemia, and 
the percentage of glycated haemoglobin. In contrast 
to these findings, a reduced plasma apelin level was 
found in patients with newly diagnosed and untreated 
T2DM [91].
Very few studies have aimed at evaluating the sig-
nificance of apelin in GDM. Aslan at al. [92] reported 
a markedly higher maternal plasma apelin level in 
GDM patients compared to control pregnant women, 
which positively correlated with its cord blood level. By 
contrast, Telejko et al. [93] demonstrated no association 
between plasma apelin concentration or apelin/APJ 
mRNA expression and GDM. Thus, the relationship of 
this novel adipokine with the pathophysiology of GDM 
remains to be elucidated. 
Retinol-binding protein 4 (RBP-4) 
RBP-4 is a 21 kDa protein synthesised in hepatocytes 
and adipocytes that participates in the metabolism of 
retinol as its carrier in the bloodstream. Yang et al. [94] 
demonstrated increased plasma RBP-4 level in insulin-
resistant mice and humans with obesity and T2DM, 
which stimulates hepatic expression of the gluconeo-
genic enzyme phosphoenolpyruvate carboxykinase 
(PEPCK) and impairs insulin signalling in muscle, 
suggesting that RBP-4 might contribute to the patho-
genesis of T2DM [94]. Graham et al. [95] supported this 
hypothesis showing the existence of a correlation be-
tween increased plasma RBP-4 level and the magnitude 
of insulin resistance in subjects with obesity, impaired 
glucose tolerance, or T2DM and in non-obese, non-
diabetic subjects with a strong family history of T2DM. 
However, this correlation remains controversial since 
no change in plasma RBP-4 level has been detected in 
subjects who developed insulin resistance [96]. 
There are no consistent results on plasma RBP-4 level in 
normal pregnancy. Ueland et al. [97] reported a significant 
increase in fasting RBP-4 from early to late pregnancy, 
and this change was associated with a decline in insulin 
sensitivity. In contrast, Inoue et al. [98] demonstrated that 
RBP-4 level tended to decrease after early gestation with 
no obvious difference between mid- to late-gestation. 
Reports on circulating RBP-4 in GDM have also yielded 
conflicting results. There exist studies showing increased 
[99], decreased [100], or even unaltered [101] plasma 
concentration of this adipokine during pregnancy compli-
cated by GDM. Therefore, the precise role of RBP-4 in nor-
mal human pregnancy and GDM remains to be clarified.
Vaspin
Vaspin, belonging to the serine protease inhibitor fam-
ily, is a novel 392–395 amino acid adipokine that was 
identified in visceral white adipose tissue of obese, 
diabetic Otsuka Long-Evans Tokushima fatty (OLEFT) 
rats [102]. In this experimental animal model, visceral 
vaspin expression and its plasma level were decreased 
with worsening of diabetes and body weight loss [102]. 
Vaspin has also been demonstrated to improve glucose 
tolerance and insulin sensitivity in diet-induced obese 
rodents and may also normalise altered expression of 
genes relevant to insulin resistance [102].
In human adipose tissue, vaspin mRNA expression 
was undetectable in lean individuals (BMI < 25), whereas 
it was fat depot specific in obese subjects [103]. Visceral 
vaspin mRNA expression positively correlated with BMI 
and percentage body fat and negatively correlated with 
plasma glucose concentration at 2-h oral glucose toler-
ance test (OGTT). Subcutaneous vaspin mRNA expres-
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sion negatively correlated with waist-to-hip ratio, fasting 
plasma insulin concentration, and glucose infusion rate 
during steady state of euglycaemic-hyperinsulinaemic 
clamp. It has been suggested that induction of vaspin 
mRNA expression in human adipose tissue might repre-
sent a compensatory mechanism associated with obesity, 
insulin resistance, and T2DM [103].
Vaspin is also present in human placenta, where 
its expression increases gradually during pregnancy, 
reaching the highest level at the end of gestation [104]. 
Vaspin expression predominates in cytotrophoblasts 
and syncytiotrophoblasts during the first trimester, 
whereas its presence is exclusively limited to syncytio-
trophoblasts in the third trimester [104]. Food restric-
tion increases placental vaspin expression, implying its 
regulation by energy status in placenta [104].
To date, the role of vaspin in normal pregnancies 
remains poorly understood. Giomisi et al. [105] reported 
a lower plasma vaspin level in pregnant women than 
non-pregnant controls that negatively correlated with 
their lipid parameters (total cholesterol, TGs, LDL-
cholesterol), implying that vaspin might be used as 
a surrogate marker of lipid metabolism in pregnancy. 
Additionally, plasma vaspin level positively corre-
lated with adiponectin in pregnant and non-pregnant 
women, but was not correlated with BMI, serum insulin 
level, or the quantitative insulin sensitivity check index 
(QUICKI) in both groups, suggesting that vaspin can-
not serve as a biomarker of insulin resistance in either 
pregnant or non-pregnant women [105]. 
Little is also known about the significance of vaspin 
in GDM. Stepan et al. [106] showed no significant differ-
ence in circulating vaspin concentration between GDM 
women and normal pregnancy. Furthermore, there was 
no correlation between vaspin level and parameters of 
insulin sensitivity or lipid metabolism in pregnant subjects. 
Recently, Gkiomisi et al. [107] revealed a similar reduction 
in vaspin level from the second trimester to postpartum 
in women with and without GDM. Interestingly, vaspin 
positively correlated with insulin, the homeostasis model 
assessment-insulin resistance (HOMA-IR) and TGs, and 
negatively correlated with QUICKI in GDM women in 
the third trimester of pregnancy, but not in the second 
trimester or postpartum [107]. Additionally, insulin treat-
ment did not change vaspin level in GDM patients, sug-
gesting that exogenous administration of insulin does not 
affect the adipokine [107]. Taken together, more research is 
needed to define the physiological and pathophysiological 
significance of vaspin.
Omentin-1 
Omentin-1, also named intelectin-1, is a novel 34 kDa 
visceral fat depot-specific adipokine. Its gene is located in 
the 1q22-q23 chromosomal region, which is considered to 
be linked to T2DM in various populations [108, 109]. Thus, 
omentin could be a candidate gene for T2DM susceptibil-
ity in humans. Indeed, it has been demonstrated in vitro 
that treatment with recombinant omentin-1 enhances 
insulin-stimulated glucose uptake in human subcutane-
ous and omental adipocytes, implying its beneficial effect 
on insulin sensitivity [110]. Moreover, several clinical stud-
ies have revealed reduced plasma omentin level in obese 
patients as well as patients with T2DM or polycystic ovary 
syndrome that negatively correlates with BMI, fasting 
insulin, and HOMA-IR [111–114]. 
Recently, Barker et al. [115] demonstrated that human 
placenta also secretes omentin-1 and its release from 
placenta is markedly higher than from omental adipose 
tissue. In that study, omentin-1 level was higher in the 
first trimester than in the second trimester of pregnancy, 
suggesting increased omentin-1 clearance in the later 
stages of pregnancy or reduced secretion from maternal 
adipose tissue. Additionally, there was no difference in 
omentin-1 level between 28 weeks gestation and seven 
weeks postnatal. In respect to GDM, it has been shown 
that maternal omentin-1 level is significantly lower in non-
obese GDM women compared to non-obese NGT women, 
whereas it is not different between obese GDM and obese 
NGT women [115]. In addition, maternal obesity or GDM 
does not affect cord plasma omentin-1 level [115]. Further 
experimental studies are required to understand the role 
of omentin-1 in GDM.
Conclusions
GDM is a highly complex process involving multiple 
factors which the identification as well as determination 
of the molecular mechanisms by which these factors 
participate in the pathophysiology of GDM is currently 
a serious challenge [116]. In recent years, considerable 
progress has been made in respect of the involvement 
of adipose tissue-derived hormones in the pathophysi-
ology of GDM. Although the significance of leptin and 
adiponectin is relatively well characterised in glucose 
and lipid metabolism in diabetes, the molecular mecha-
nisms by which these adipokines potentially exert their 
effects on insulin action are not completely defined and 
require further studies. Additional clinical studies are 
also needed to clarify discrepancies between findings 
in rodent models and humans in respect of resistin 
dysregulation in diabetic patients.
Given that the list of molecules identified as adipokines 
has grown over recent years, more well-controlled hu-
man studies should be performed to define whether or 
not dysregulation of newly discovered adipokines such 
as visfatin, apelin, RBP-4, vaspin, and omentin directly 
contribute to the pathophysiology of GDM. 
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